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Background: Alzheimer’s disease (AD) is characterized by the abnormal accumulation of extracellular beta-amyloid
(Abeta) plaques, intracellular hyperphosphorylated tau, progressive synaptic alterations, axonal dystrophies, neuronal
loss and the deterioration of cognitive capabilities of patients. However, no effective disease-modifying treatment
has been yet developed. In this work we have evaluated whether chronic lithium treatment could ameliorate the
neuropathology evolution of our well characterized PS1M146LxAPPSwe-London mice model.
Results: Though beneficial effects of lithium have been previously described in different AD models, here we
report a novel in vivo action of this compound that efficiently ameliorated AD-like pathology progression and
rescued memory impairments by reducing the toxicity of Abeta plaques. Transgenic PS1M146LxAPPSwe-London
mice, treated before the pathology onset, developed smaller plaques characterized by higher Abeta compaction,
reduced oligomeric-positive halo and therefore with attenuated capacity to induce neuronal damage. Importantly,
neuronal loss in hippocampus and entorhinal cortex was fully prevented. Our data also demonstrated that the axonal
dystrophic area associated with lithium-modified plaques was highly reduced. Moreover, a significant lower accumulation
of phospho-tau, LC3-II and ubiquitinated proteins was detected in treated mice. Our study highlights that this switch
of plaque quality by lithium could be mediated by astrocyte activation and the release of heat shock proteins, which
concentrate in the core of the plaques.
Conclusions: Our data demonstrate that the pharmacological in vivo modulation of the extracellular Abeta
plaque compaction/toxicity is indeed possible and, in addition, might constitute a novel promising and
innovative approach to develop a disease-modifying therapeutic intervention against AD.
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In Alzheimer’s disease (AD), the abnormal accumulation of
extracellular beta-amyloid (Abeta) plaques and intracellular
hyperphosphorylated tau induces progressive synaptic
alterations, axonal dystrophies, neuronal loss and the
deterioration of cognitive capabilities of patients [1,2].
In spite to the relatively large information about the AD
pathology, no effective disease-modifying treatment has
been yet developed. Within the different compounds tested,
lithium, a primary drug to treat bipolar disorder, has also
been suggested as a potential treatment against AD [3-6].
In fact, clinical studies indicated that lithium could be
preventive in patients with MCI, whereas no beneficial
effects were observed in mild to moderate AD [4]. In
addition, epidemiological studies also reported a reducing
risk of AD in patients with bipolar disorders treated with
Li [5]. Thus, lithium may indeed constitute a useful
preventive treatment for individuals at high risk of AD
and/or preclinical stages of the disease.
The neuroprotective mechanisms of lithium are not com-
pletely understood. In AD models, lithium could reduce
the AD pathology inhibiting (directly and/or indirectly)
the activity of the tau kinase GSK-3beta. Whereas this
inhibition would preclude tau phosphorylation [7,8],
dystrophy formation and neuronal degeneration [9,10], the
therapeutic benefits of this treatment have been questioned
[11]. On the other hand, lithium also mediated the inhibition
of inositol monophosphatase and the induction of
mTOR-independent autophagic process [12,13]. This
induction may be important in the prevention or attenuation
of neurodegeneration associated with aggregated proteins.
Moreover, since the accumulation of autophagic vesicles
could also be implicated in the formation of axonal
dystrophies in AD models [14-17], lithium should alleviate
the progression of these pathological features. However,
while several studies have shown beneficial effects in
lowering Abeta load [18-20], others reported no effect or
even increased Abeta production [11,21,22].
The origin of these controversies is currently un-
known. Among other factors, the different AD models,
the different protocols of lithium administration or dos-
age and, perhaps more relevant, the partial neuropathol-
ogy displayed for most of the AD models, could explain
the discrepancies between the different effects of lith-
ium treatment in transgenic models.
In this work we have evaluated the effect of chronic oral
lithium treatment using the bigenic PS1M146LxAPPSwe-
London mice. This model displayed early degeneration
of O-LM and HIPP interneurons (SOM/NPY-positive),
in hippocampus and entorhinal cortex [23,24]. These
GABAergic cells are implicated in memory/learning
processes and degenerate in AD patients [25,26]. Our data
demonstrated that chronic (from 3- to 9-month-old) orallithium administration, initiated before the onset of
Abeta deposits, efficiently prevented most of the early
neuropathological manifestations of our PS1xAPP model.
Lithium prevented the neuronal loss (at both hippocampus
and entorhinal cortex), reduced the tau phosphorylation and
the formation of axonal dystrophies and, in consequence,
ameliorated behavioral/memory deficits observed at this age.
These effects were mediated by increasing the compaction of
Abeta plaques and lowering their toxic oligomeric
halo. This modification on Abeta deposits toxicity is a novel
disease-modifying effect of lithium, acting through the
astrocytes and the release of heat shock proteins (Hsps).Methods
Transgenic mice and lithium treatment
Generation of PS1M146LxAPP751Swe-London (PS1xAPP)
mice has been reported previously [27]. Heterozygous
PS1xAPP double transgenic mice (C57BL:6 background)
were generated by crossing homozygous PS1 transgenic mice
with heterozygous Thy1-APP751SL mice. Only male mice
were used in this work.
As controls, we used age-matched non-transgenic
(C57BL:6) male mice (WT) or hemizygous PS1M146L
littermates (PS1). The PS1 mice displayed no apparent
differences with WT mice, at the age used in this work
[24] (see also Figures 1 and 2A). Only PS1xAPP mice
model accumulated Abeta plaques. Thus, to specifically
assess the potential therapeutic effect of lithium on the
Abeta pathology, we reasoned that PS1 mice would be a
better control than WT mice. An additional lithium
treated PS1 group was also used as control for lithium
treatment.
For lithium treatment, PS1 and PS1xAPP mice (3 month
old at the beginning of treatment) were randomly divided
into two groups (n = 25 each). Mice were fed, ad libitum,
with standard mice diet (2014 Teklad Global 14% Protein
Rodent Maintenance Diet, Harlan, Spain) or standard
mice diet supplemented with lithium carbonate (1.2 g/kg
2014 diet, Harlan, Spain). The lithium group received an
additional drinking bottle containing NaCl (0.7%). The
treatment was continued for 6 months. The control and
treated mice were weighted weekly and no significant
weight loss was detected (29.20 ± 1.09 g vs 27.5 ± 2.2 g for
control and Li-treated PS1xAPP mice, respectively). For
the plasmatic Li content, mice were bled (100 μl) from the
ocular artery. The plasmatic lithium levels were stable
during the treatment and also were within the therapeutic
range: 0.44 ± 0.07 mEquiv/L (n = 10) after 71 days of
treatment or 0.38 ± 0.05 mEquiv/L (n = 10) at the end
of treatment. This treatment was well tolerated with a low
mortality during this period. (PS1 control 0%; PS1 lithium,
0%; PS1xAPP control, 20%; PS1xAPP lithium, 7.4%).
Figure 1 Lithium treatment improved the behavioral/memory deficiencies of PS1xAPP mice. (A) Open-field test. One-way ANOVA revealed
significant differences between groups in both distance (F(3,24) = 6.33; p = 0.006) and velocity F(3,24) = 8.02, p = 0.002). Post-hoc analysis showed
significant differences in PS1xAPP control compared with WT/PS1 and PS1xAPP lithium (p < 0.05). (B) Behavioral protocol and memory measures.
Sixty min after habituation to the open-field, animals received three samples trials with 120 min inter-trial as depicted. Each symbol (triangle and star)
represents one type of object. One-way ANOVA F(3,24) = 21.15 p = 0.0001) revealed significant differences between groups in place memory index.
Post-hoc analysis showed significant difference in PS1xAPP control compared with WT/PS1 controls and PS1xAPP lithium.
Trujillo-Estrada et al. Acta Neuropathologica Communications 2013, 1:73 Page 3 of 16
http://www.actaneurocomms.org/content/1/1/73After behavioral tests, control and lithium-treated
mice were anesthetized with sodium pentobarbital
(60 mg/kg), and transcardially perfused with 0.1 M
phosphate buffered saline (PBS). Then, mice brain
was quickly removed and one hemibrain dissected
(cortex and hippocampus), frozen and stored at −80°
C while the other hemibrain was fixed by immersionwith 4% paraformaldehyde, 75 mM lysine, 10 mM
sodium metaperiodate in 0.1 M phosphate buffer
(PB), pH 7.4 for 5 days at 4°C. Fixed hemibrains
were cryoprotected in 30% sucrose, sectioned at 40
μm thickness in the coronal plane on a freezing
microtome and serially collected in wells containing
cold PBS and 0.02% sodium azide.
Figure 2 Lithium treatment avoided neuronal loss in the hippocampus of PS1xAPP mice. (A) The expression of SOM and NPY
(n= 20 mice per group) was significantly lower in PS1xAPP control group (ANOVA F(4,96) = 49.63, p = 0.00001. Tukey p < 0.05 or F(4,96) = 27.24,
p = 0.0001, Tukey p < 0.05 for SOM and NPY respectively). WT, PS1 (control or lithium) and PS1xAPP lithium displayed no differences. B) SOM
(b1-b3) or NPY (b4-b6) immunolabeled sections through CA1 subfield of PS1 control or PS1xAPP control and lithium groups. C) Total SOM or
NPY cell number in hippocampus proper and dentate gyrus was assessed by stereology (n = 5 per genotype and treatment). WT and PS1 groups
displayed no differences and data were pooled. Only control PS1xAPP displayed a significant reduction in SOM (ANOVA F(2,22) = 14.57, p = 0.00002
or F(2.22) = 11.84, p = 0.0008 for hippocampus proper and dentate gyrus, respectively) and NPY (ANOVA F(2,22) = 17.02, p = 0.0001 or F(2,22) = 6.87,
p = 0.008 for hippocampus proper and dentate gyrus, respectively) cell number. D) NPY-positive dystrophies (black arrows) in CA1 subfield of PS1xAPP
control (d1) and lithium mice (d2) (open arrows: NPY cell bodies). (d3) Quantitative analysis (n = 4 mice per group; 6 sections per animal) demonstrated
the existence of a significant reduction of NPY-positive dystrophic area (μm2) in PS1xAPP lithium. E) Co-localization of SOM (green) and AT8 (red) in
dystrophies assessed using confocal microscopy. In PS1xAPP control mice (e1 to e3), SOM positive dystrophies (arrows), surrounding Abeta plaque
(asterisk), were positive for AT8. Lithium produced a reduction in both SOM (e4) and AT8 (e5) positive dystrophies and in the co-localization between
SOM and AT8 in dystrophies (e6). Scale bars: b1-b6 100 μm; d1 and d2 100 μm; e1-e6 20 μm.
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with the animal research regulations (RD53/2013 and
2010/63/UE) from Spain and European Union, and with
the approval of the Committees of Animal Research
from the University of Seville (Spain) and the University
of Malaga (Spain).
Behavioral studies
All experiments were conducted on age-matched male
WT (n = 10), PS1 (n = 10), PS1xAPP control (n = 9) and
PS1xAPP lithium-treated (n = 9) mice. Mice were tested at
9 month of age, two days previous to sacrifice. All testing
were performed in the light period of the light/dark
cycle and the experimenter was blind to the genotypes andtreatment of mice. Animals were adapted to the experimen-
tal conditions for 6 days before behavioral testing. All mice
were moved to the testing room in their home-cage and
kept in the room during 1 hour to habituate to the new lo-
cation; then, they were handled gently each day briefly in
order to minimize non-specific stress. The behavioral
experiment protocol was conducted as shown in Figure 1.
Open-field test
Besides the use of the open-field to habituate animals to
the cage before the object recognition test, we examined
motor function by means of spontaneous locomotor
activity [28]. In this test, mice were placed in the centre of a
square-shape arena (45 cm × 45 cm) and were allowed
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thoroughly cleaned with 70% ethanol solution after
each trial. The locomotor activity was measured by
an automated monitoring system (Ethovision, Noldus,
The Netherlands). Distance travelled and velocity was
quantified.
Object recognition test
The object recognition test is based in the natural tendency
of rodents to explore objects (spontaneous exploratory
behavior). In the present study, we used a modified
protocol [29] based in the preference for the “old familiar
object” over the “recent familiar object” and the preference
for a novel location. Sixty minutes after habituation to the
open-field, animals were first exposed to four identical
objects arranged in a triangle shaped configuration and
allowed to explore them for 10 minutes (Sample 1). After a
delay of 2 hours, the mice received a second sample trial
identical to the first, except that a novel set of four identical
objects were present (Sample 2). The test trial started after
2 hours interval and lasted for 5 minutes. In the test trial,
two objects from both samples 1 and 2 (“old familiar” and
“recent familiar” objects, respectively) were arranged in a
quadratic shape configuration, so one old object and one
recent object were present in a familiar position while the
other two were displaced to a new position (see Figure 1B
for details). The type of object used as “old” and “recent”
was counterbalanced across mice. All objects were made of
plastic to prevent material preference and for an easier
cleaning to prevent odor cues. The two sets of objects were
different in size, form and color. The arena and objects
were thoroughly cleaned with 70% ethanol solution after
each trial. The time spent by the mice exploring each
object was analyzed observationally. Indeed, the basic
measure was the time spent by the mice exploring objects
during the sample phases and during the test trial.
Additionally, two discrimination indexes were calculated
for the test trial: an object recognition ratio (total time
exploring “old familiar” objects/total time exploration) and
a location recognition ratio (total time exploring displaced
objects/total time exploration). The time was recorded
only when the mice touched the object with its nose or
forepaws. Turning around, walking over the object, rearing
above the object or resting close to the object was not
deemed to be exploration. Moreover, locomotor activity
was also measured with the software Ethovision XT 7.0
(Noldus, The Netherlands).
RNA and total protein extraction
Total RNA from mice hippocampi was extracted using
Tripure Isolation Reagent (Roche) as described previously
[23,24,30,31]. After isolation, RNA integrity was assessed
by agarose gel electrophoresis. The yield of total RNA was
determined by measuring the absorbance (260:280 nm)of isopropanol-precipitated aliquots of the samples.
The recovery of RNA was comparable in all studied
groups (1.2-1.5 μg/ mg of tissue). The protein pellets,
obtained using the Tripure Isolation Reagent and
isopropanol-mediated precipitation, were resuspended
in 4% SDS and 8 M urea in 40 mM Tris–HCl, pH 7.4
and rotated overnight at room temperature to get com-
plete protein solubilization.
Retrotranscription and real-time RT-PCR
Retrotranscription (RT) was performed using random
hexamers, 4 μg of total RNA as template and High-
Capacity cDNA Archive Kit (Applied Biosystems) follow-
ing the manufacturer recommendations [24,30]. For real
time RT-PCR, commercial TaqmanTM probes (Applied
Biosystems) were used for amplification. PCR reactions
were carried out using either ABI Prism 7000 or 7900HT
sequence detector systems (Applied Biosystems). A standard
curve was first constructed for every assay, using increasing
amounts of cDNA. In all cases, the slope of the curves indi-
cated optimal PCR conditions (slope 3.2-3.4). The cDNA
levels of the different mice were determined using GAPDH
as housekeeper. Therefore, GAPDH amplification was done
in parallel with the gene to be analyzed, and this dada used
to normalize target gene results.
Independently of the analyzed gene, results were always
expressed using the comparative Ct method, following the
Bulletin number 2 from Applied Biosystems. As a control
condition, we selected 9 month-old WT mice with control
diet. In consequence, the expression of all tested genes, for
all ages and mice types, was referenced to the expression
levels observed in this group.
Antibodies
For this study the following primary antibodies were used:
anti-Neuropeptide Y (NPY) rabbit polyclonal (1:5000, Sigma);
anti-Somatostatin (SOM) goat polyclonal (1:1000, Santa Cruz
Biotechnology); anti-Abeta (clone 6E10) mouse monoclonal
(1:5000, Signet); anti-oligomeric amyloid-beta OC rabbit
polyclonal (1:5000, Millipore); anti-Abeta42 rabbit polyclonal
(1:5000, Abcam); anti-phospho-tau pSer202/Thr205 mouse
monoclonal (clone AT8) (1:250, Pierce); anti-microtubule-
associated protein 1 light chain 3 (LC3) rabbit polyclonal
(1:500, Cell Signaling); anti-GFAP rabbit polyclonal (1:10000,
Dako); anti-ubiquitin rabbit polyclonal (1:5000, Dako);
anti-Hsp70 rabbit polyclonal (1:5000, Neomarkers) anti-Hsp60
mouse monoclonal (1:1000, Santa Cruz, Biotechnology),
anti-Hsp27 rabbit polyclonal (1:1000, Sigma).
Western blot
Western blots were performed as described [32]. Briefly,
5–20 μg of proteins from the different samples were
loaded on 16%-SDS-tris-tricine-PAGE or 12%-SDS-tris-
glycine-PAGE and transferred to nitrocellulose (Hybond-C
Trujillo-Estrada et al. Acta Neuropathologica Communications 2013, 1:73 Page 6 of 16
http://www.actaneurocomms.org/content/1/1/73Extra; Amersham). After blocking, using 5% non-fat milk,
membranes were incubated overnight, at 4°C, with the
appropriate antibody Membranes were then incubated
with the corresponding horseradish-peroxidase-conjugated
secondary antibody (Dako, Denmark) at a dilution of
1:8000. Each blot was developed using the ECL-plus
detection method (Amersham) and quantified using Image-
Quant Las 4000 mini gold (GE Healthcare Bio-Sicences).
For normalization purposes, proteins were first estimated
by Lowry and protein loading corrected by beta-actin. In
each experiment, the intensity of bands from PS1 control
fed were averaged and considered as 1 relative unit. Data
were always normalized by the specific signal observed in
PS1 control group.
Immunohistochemistry
Serial sections from control and lithium-treated transgenic
mice (n = 6 per group) were processed in parallel for
immunostaining using the same batches of solutions to
minimize variability in the immunohistochemical labeling
conditions. Free-floating sections were first treated with
3% H2O2/10% methanol in PBS, pH 7.4 for 20 min to
inhibit endogenous peroxidases, and with avidin-biotin
Blocking Kit (Vector Labs, Burlingame, CA, USA) for
30 min to block endogenous avidin, biotin and biotin
binding proteins. Sections were immunoreacted with the
primary antibody over 24 or 48 h at room temperature.
The tissue bound primary antibody was then detected by
incubating for 1 h with the corresponding biotinylated
secondary antibody (1:500 dilution, Vector Laboratories), and
then followed by incubating for 90 min with streptavidin-
conjugated horseradish peroxidase (Sigma-Aldrich)
diluted 1:2000. The peroxidase reaction was visualized
with 0.05% 3-3-diaminobenzidine tetrahydrochloride
(DAB, Sigma-Aldrich) and 0.01% hydrogen peroxide in
PBS. Except for Abeta42 immunolabeling, the chromogen
solution contained 0.03% nickel ammonium sulphate for a
blue reaction product. For double NPY-6E10 immunohisto-
chemical labeling sections were first incubated with anti-
NPY as described above. After the DAB-nickel reaction
(dark blue end product), sections were the incubated with
anti-6E10 antibody. The second immunoperoxidase
reaction was developed with DAB only (brown reaction
end product). After DAB, sections immunolabeled for
Ubiquitin or LC3 antibodies were incubated 3 min in a
solution of 20% of Congo red. Sections were then mounted
on gelatin-coated slides, air dried, dehydrated in graded
ethanol, cleared in xylene and coverslipped with DPX (BDH)
mounting medium. Specificity of the immune reactions was
controlled by omitting the primary antisera.
For double or triple immunofluorescence labelings,
sections were first sequentially incubated with the
indicated primaries antibodies followed by the cor-
responding Alexa 488/568//405 secondary antibodies(1:1000; Invitrogen). GFAP- and OC-immunolabeled sec-
tions were stained with 0.02% thioflavin-S in 50° ethanol
for 5 min. Sections processed for immunofluorescence
were mounted onto gelatin-coated slides, coverslipped with
0.01M PBS containing 50% glycerin and then examined
under a confocal laser microscope (Leica SP5 II).
Stereological analysis
Immunopositive cells for SOM or NPY belonging to
control and lithium-treated animal groups (n = 5 per group)
were stereologically quantified in hippocampus proper and
dentate gyrus of hippocampus according to the optical
fractionator method. Briefly, the quantitative analyses were
performed using an Olympus BX61 microscope interfaced
with a computer and an Olympus DP71 digital camera, and
the NewCAST (Computer Assisted Stereological Toolbox)
software package (Olympus, Denmark). Cell counting was
done through the rostrocaudal extent of the hippocampus
(between −0.94 mm anterior and 3.64 mm posterior to
Bregman coordinates). Neurons were quantified in every
seventh section (with a distance of 280 μm), and an average
of 6–7 sections was measured in each animal. CA and
dentate gyrus boundaries were defined according a stand-
ard mouse stereotaxic brain atlas using a 4x objective and
the number of neurons was counted using a 100×/1.35
objective. We used a counting frame of 1874.2 μm2 with
step lengths of 78.93 × 78.93 μm. The total cell number
was estimated using the optical fractionators formula, N =
1/ssf × 1/asf × 1/hsf ×∑Q ‐, where ssf represents the section
sampling fraction, asf is the area sampling fraction, which is
calculated by dividing the area sampled with the total area
of the layer, hsf stands for the height sampling fraction,
which is calculated by dividing the height sampled (10 μm
in this study) with the section thickness, and ∑Q- is the
total count of somatic profiles counted for the entire area.
The precision of the individual estimations is expressed by
the coefficient of error (CE) using the following formula:
CE = 1/Q× (3A ‐ 4B +C/12)1/2, where A =∑Qi2, B =∑Qi ×
Qi + 1, C =∑Qi × Qi + 2. The CEs ranged between 0.07 and
0.1. An investigator who was blind to the experimental
conditions performed neuronal profile counting.
Plaque size
To determine the size of the plaques, anti-Abeta42
immunostained sections from control and lithium-treated
mice (n = 6 per group) were analyzed using the nucleator
method with isotropic probes by the NewCAST software
package from Olympus stereological system. CA1 subfield
was analyzed using a counting frame of 7155.3 μm2. For
individual plaque measurement a 40x objective was used.
Number of plaques/mm2 falling into surface categories
(ranging from <200 μm2 to >2000 μm2) was calculated.
Each analysis was done by a single examiner blinded to
sample identities.
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NPY immunostained sections from control and lithium-
treated animals were observed under a Nikon Eclipse 50i
microscope using a 10x objective and CA1 images were
acquired with a Nikon DS-5M high-resolution digital
camera. The camera settings were adjusted at the start
of the experiment and maintained for uniformity. Digital
images (5 sections/mouse) from control and treated
mice (n = 6 per group) were analyzed using Visilog 6.3
analysis program (Noesis, France). The area occupied by
the NPY-positive dystrophic neurites was identified by
level threshold which was maintained throughout the
experiment for uniformity. The CA1 area in each image
was manually outlined and the positive somata were
removed by manual editing. The area occupied by NPY
dystrophies was estimated and defined as (sum dystrophies
area measured/sum CA1 area analyzed) × 100. The mean
and standard deviation (SD) of the dystrophies area
were determined using all the available data. Quantitative
comparisons were carried out on sections processed
simultaneously using same batches of solutions.NPY dystrophies associated to plaques
The area of NPY dystrophic neurites intimately associated
to plaques of different sizes (<200 μm2, 200–500 μm2,
500–2000 μm2 and >2000 μm2) was measured in double
6E10/NPY immunostained CA1 sections from control and
lithium-treated animals. Images were photographed using a
20x objective with a Nikon Eclipse 50i microscope coupled
to a Nikon DS-5M high-resolution digital camera. Digital
images (5 sections/mouse) from control and lithium-treated
animals (n = 3 per group) were analyzed using Visilog 6.3
analysis program (Noesis, Frace) to determine the NPY
dystrophies area associated to each plaque size group.Plaque compaction analysis
Abeta42 immunostained hippocamapal sections from
control and lithium-treated animals were observed under a
Nikon Eclipse 50i microscope and CA1 plaques were
photographed using a 10x objective. Images were acquired
with a Nikon DS-5M high resolution digital camera.
The camera settings were adjusted at the start of the
experiment and maintained for uniformity. Digital images
(5 sections/mouse, n = 5 per group) were analyzed using
Visilog 6.3 analysis program (Noesis, France). Abeta42
staining density was identified by bright-level threshold,
the level of which was maintained throughout the experi-
ment for uniformity. The gray-scale image was converted
to a binary image for estimating the optical density which
was defined as pixel units and related with the plaque size
(μm2 which area was measured using the same program).
Quantitative comparisons were performed on sections
processed at the same time.Oligomeric plaque halo
To analyze the oligomeric Abeta halo located at the
periphery of the plaques, 40 μm floating sections were
first stained with Thioflavin-S and then followed by an anti-
body specific to oligomers of Abeta (OC antibody; 1:5000)
visualized with anti-rabbit Alexa568-conjugated secondary
antibody (Invitrogen A10042; 1:1000). Images of 1,024 ×
1,024 pixels were acquired by using a Leica SP5 II confocal
laser microscope. A total of 15 plaques per animal were
randomly photographed in CA1 subfield of control and
treated animals (n = 3 per group). Laser settings were
adjusted at the start of the experiment and maintained for
uniformity. Images were analyzed using LAS AF Lite pro-
gram (Leica). Plaque area was determined for Thioflavin-S
staining (plaque core in green color) and OC immunostain-
ing (oligomeric Abeta in red color) and the difference
between the OC area and the core area was considered as
the oligomeric halo surrounding plaques.
Statistical analysis
Normality of data was first assessed by using Kolmogorov-
Smirnov test. Normally distributed data were expressed
and represented as mean ± SD. Non-normal distributed
data were represented using box-plot. For normally
distributed data, means were compared using ANOVA
followed by Tukey test (more than two groups) or t-test
(for two group comparisons). Non-normal data were com-
pared by Wilcoxon (for two groups) or Kruskal-Wallis
tests (more than two groups). The significance was set at
95% of confidence. Fit and comparison of linear regression
was done using multiple regression analysis followed by
conditional sum of squares. In all cases Statgraphics plus
3.1 was used.
Results
Lithium treatment rescued behavioral/memory deficits
First, we tested whether lithium administration was able
to improve the behavioral/memory deficiencies observed
in the 9 month-old control PS1xAPP transgenic model.
From the different tasks performed (i.e. Morris water
maze), only open-field and novel object recognition
showed statistical differences between PS1xAPP and WT
or PS1 control mice. No differences between WT and
PS1 mice were observed.
In the open-field test, control PS1xAPP mice displayed
significant lower activity than either WT or PS1 mice
(Figure 1A). There was a significant reduction in both
total distance and velocity. No significant differences
were observed in time in the periphery or center of the
field, or in the immobility periods (data not shown). Also,
no differences between PS1xAPP and control groups were
observed in fecal boli depositions (not shown). Thus, the
PS1xAPP mice were hypoactive as reported in other AD
models, such as the 3xTg-AD [28]. As we shown, this mild
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lithium treatment (Figure 1A).
We next evaluated the episodic-like memory using novel
object recognition tests. These tests are based on the
preference for the “old familiar object” over the “recent
familiar” object and the preference for a novel location [29].
Although no differences between groups were observed in
the object recognition ratio (Figure 1B), control PS1xAPP
mice displayed a significant cognitive deficit in object
location memory (which is hippocampus-dependent), com-
pared with PS1/WT mice. Remarkably, full recovery of
this spatial memory impairment was observed in lithium-
treated PS1xAPP mice, which displayed no differences
with the control groups (Figure 1B). Therefore, these data
indicated that early oral lithium administration prevents
the spatial memory deterioration in PS1xAPP mice.
Lithium administration prevented neuronal loss
As we have reported previously, early Abeta deposition
in this PS1xAPP model is paralleled by a selective and
significant decrease in the number of SOM and NPY
positive GABAergic neurons in the hippocampal formation
and the entorhinal cortex [23,24], (see also Figure 2A, B
and C). Furthermore, SOM/NPY positive cells displayed a
prominent axonal pathology (Figure 2D), with multiple dys-
trophies (positive also for phospho-tau) that surrounded
Abeta plaques (Figure 2E). The early and extensive
degenerative pathology of the GABAergic cells, including
neuronal death, could be used as a surrogated marker to
evaluate the neuroprotective effect of lithium at the initial
stages of the disease.
We thus analyzed, at the hippocampal formation, the
SOM and NPY expression by qPCR; the number of SOM
or NPY immunopositive somata, by stereological quantifica-
tion, and their axonal dystrophy loading. Lithium produced
an effective prevention of the neurodegenerative process
exhibited by this neuronal population in PS1xAPP mice
(Figure 2). In fact, the mRNA expression for both neuropep-
tides, SOM and NPY, was virtually identical in lithium-
treated PS1xAPP mice, as compared with control groups
(Figure 2A). Furthermore, stereological determination of the
SOM or NPY cell number (Figure 2B and C) further
demonstrated the protective effect of lithium on these
neurons in hippocampus proper (O-LM cells) and dentate
gyrus (HIPP cells). PS1 and WT mice displayed not
differences and lithium treatment of PS1 mice did not alter
the expression of either SOM or NPY neuropeptides
(see Figure 2A) or the number of SOM or NPY positive
cells (data in Figure 2C were pooled from WT, PS1 control
and lithium groups). For subsequent experiments, only
PS1 control and PS1 lithium mice were included.
The same samples were used for the stereological
quantification of SOM or NPYcell number at the entorhinal
cortex, another early affected brain region. As previouslyreported [23], double transgenic mice displayed in this
cortical region a significant decrease in the number of both
SOM (4,207± 1,119 cell/mm3, n= 4, vs 8,596 ± 803 cell/mm3,
n = 6, for control PS1xAPP and PS1 mice, respect-
ively, p < 0.05; 52.2 ± 13.1% of reduction) and NPY
(1,770 ± 227 cell/mm3, n = 4, vs 3,062 ± 363 cell/mm3, n = 6,
for control PS1xAPP and PS1 mice, respectively, p < 0.05;
58.4 ± 7.1% of reduction) immunopositive GABAergic cells.
However, after lithium treatment, the number of both neur-
onal populations did not differ between PS1/APP and PS1
groups (7,087 ± 1,097 cell/mm3 or 3,003 ± 423 cell/mm3,
n = 4, for SOM and NPY, respectively; 17.6 ± 12.8% or
1.9 ± 13.8% of reduction).
Thus, early lithium intervention was highly effective
preventing the SOM/NPY neuronal loss in both the
hippocampal formation and the entorhinal cortex of
PS1xAPP model.
Another prominent pathological feature of this neuronal
population in our PS1xAPP mice is the extensive develop-
ment of axonal dystrophies associated to Abeta plaques
[15] (Figure 2D and E). Importantly, lithium treatment
produced, in parallel with the prevention of the SOM/NPY
cell loss, a prominent reduction of the axonal dystrophy
pathology in these cells. In fact, lithium treated PS1xAPP
mice displayed an obvious and highly significant decrease
(−60.2%) in the NPY positive dystrophic area (Figure 2D,
d1, d2 and d3). Also, there was a decrease in the AT8- and
SOM-positive dystrophies (Figure 2E). Therefore, lithium
avoided SOM/NPY neurodegeneration and improved the
cell integrity, reducing the axonal degeneration of this
highly vulnerable neuronal population.
Lithium treatment ameliorated axonal/synaptic pathology
by reducing abnormal intracellular protein accumulation
PS1xAPP mice accumulated phospho-tau, LC3-II and
ubiquitinated proteins in axonal dystrophies surrounding
Abeta plaques (Figure 3; see also [15,16]). Thus, in agreement
with the preservation of SOM/NPY neurons, lithium also
reduced both the total AT8-positive phospho-tau levels, de-
termined by western blots (Figure 3A), and the AT8-positive
dystrophies, detected by immunohistochemistry (Figure 3B).
Furthermore, lithium also reduced the steady-state levels of
both LC3-II and ubiquitinated proteins (see Figure 3C). In
fact, the steady-state levels of both LC3-II and ubiquitinated
proteins were similar to those observed in the PS1 lithium
group. Immunohistochemistry also demonstrated a dramatic
reduction in both ubiquitin- and LC3-positive dystrophies,
surrounding the Abeta plaques (Figure 3D, d2 and d4).
Thus, lithium reduced the number of dystrophies and the
accumulation of intracellular proteins.
This lithium-mediated reduction of the axonal dystrophic
pathology could also ameliorate the synaptic degeneration.
Thus, we determined (by western blots) the levels of the
classic presynaptic marker synaptophysin (not shown).
Figure 3 Lithium treatment reduced the dystrophic pathology associated to Abeta plaques. A) Representative western blot (n = 7 mice
per group) and quantitative analysis of phosphorylated tau, determined using AT8 clone, of total proteins from PS1 control, PS1xAPP control and
PS1xAPP lithium-treated mice. For quantification, the AT8 levels were referred to PS1 control group. The AT8 levels were significantly increased in
PS1xAPP control mice (ANOVA F(2,18) = 22.66, p = 0.0001; Tukey p < 0.05) whereas PS1 control and PS1xAPP lithium displayed no differences.
B) Representative AT8 positive dystrophies surrounding Abeta plaques from control (b1 and b2) or lithium treated (b3 and b4) PS1xAPP mice.
C) Representative western blots and quantitative analysis of steady-state levels of LC3-II and ubiquitinated proteins in PS1 and PS1xAPP control
and treated mice (n = 4 per genotype and treatment). A clear and significant accumulation of both LC3-II (ANOVA F(3,12) = 32.52, p = 0.001) and
ubiquitinated proteins (ANOVA (F(3,12) = 63.67, p = 0.00001) was observed in PS1xAPP control mice. Lithium treatment reversed this pathology.
The post-hoc analysis, using Tukey test, was indicated in the figure. D) Ubiquitin (d1 and d2) and LC3 (d3 and d4) immunolabeled hippocampal
sections (counterstained with Congo red for Abeta plaques) of control and lithium treated PS1xAPP mice corroborated the accumulation of both
markers, associated with dystrophic neurites surrounding amyloid plaques (d1 and d3) and the patent lithium reduction (d2 and d4) in the presence of
ubiquitin and LC3 positive dystrophies. Inserts in d1-d4 showed higher magnification details of the dystrophies surrounding Abeta plaques. so, stratum
oriens; sp, stratum pyramidale; sr, stratum radiatum. Scale bars: b1, b3 50 μm; b2, b4 100 μm; d1 to d4 200μm; inserts 25 μm.
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cant reduction (0.72 ± 0.12 vs 1.00 ± 0.14 for PS1xAPP and
PS1 control, respectively, n = 7 per phenotype, Tukey
p < 0.05) whereas a completely recovery was detected
in lithium-treated PS1/APP mice (0.96 ± 0.16 for
PS1xAPP lithium, n = 9).
Taken together, these data indicated that the chronic
lithium treatment markedly reduced the plaque associ-
ated axonal dystrophy pathology, in parallel with a
reduction on the abnormal intracellular accumulation
of proteins and/or autophagic vesicles, in this PS1xAPP
model. Furthermore, lithium also decreased the putativepresynaptic degeneration observed in this transgenic
mouse model.
Lithium treatment substantially modified the morphology
and toxicity of the extracellular Abeta plaques
Next, we tested whether lithium treatment could alter
Abeta accumulation in PS1xAPP hippocampus. Data
(Table 1) indicated the absence of modifications on
either i) total monomeric Abeta (quantified by western
blot and 6E10 antibody), ii) soluble Abeta42 (quantified
by ELISA using soluble extracts) or iii) Abeta plaque
load (determined using either anti-Abeta42 or 6E10
Table 1 Abeta accumulation was not modified in the
lithium treated PS1xAPP mice
Control Lithium
Soluble Abeta42 ELISA 27.57 ± 10.74 30.14 ± 6.47
(pg/ml) n = 7 n = 7
Total Abeta Western blots 1.0 ± 0.26 0.98 ± 0.60
(relative units) 6E10 n = 18 n = 25
Abeta load Immunohistochemistry 6.83 ± 1.99 4.40 ± 1.81
(% of area) 6E10 n = 5 n = 5
Abeta42 load Immunohistochemistry 5.09 ± 2.31 3.65 ± 1.03
(% of area) Abeta42 n = 5 n = 5
Data are mean ± S.D.
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cant reduction (−62.7%) in the size of the Abeta plaques
in lithium-treated PS1xAPP mice, as compared with
PS1xAPP control group (Figures 4A, a1, a2 and quantita-
tively in a3). In fact, when the distribution of the different
sizes of the Abeta plaques was analyzed (Figure 4A, a4),
the treated group displayed a marked increase (4 fold)
in the number of small plaques (<200 μm2), with the
consequent reduction in the number of medium and large
size Abeta plaques.
This reduction of plaque size, in absence of a parallel
reduction on the total Abeta deposition, could arise of a
higher Abeta compaction. Interestingly, higher plaque
compaction could reduce the Abeta pathology [33]. We
thus determined the plaque compaction by quantifying
the optical density of Abeta42 immunostained plaques,
randomly selected by the stereological microscope (n = 800
plaques from 5 different sections and 6 different control or
treated mice; see [33]). Although the plaque compaction
was heterogeneous in both groups (Figure 4B), our data
demonstrated the existence of a highly increase (82%) in
the plaque compaction (calculated as Pixels/μm2) in the
lithium treated PS1xAPP mice (Figure 4B, b5).
The increase in plaque compaction could involve a
reduction of the putative toxic oligomeric Abeta that
surrounded or aroused from plaques (the plaque “halo”;
[34]. To quantitatively determine this possibility, the
Abeta plaques were first stained with Thioflavin-S followed
by immunostaining with the conformation-specific OC
antibody, which recognizes fibrillar Abeta oligomers.
Representative double labeled images, and the quantification
of the plaque oligomeric halo, is shown in Figure 4C
(c1 to c6, and c7, respectively). As expected, lithium treat-
ment produced a significant reduction of the OC-positive
plaque halo which might result in less toxic plaques.
To examine the impact of lithium treatment on the
toxicity of the Abeta plaques, we quantified the NPY
dystrophic area and the corresponding Abeta area in
individual plaques. Using unbiased stereological countsin NPY and 6E10 double immunostained sections
(Figure 5A), we first calculated the proportion of Abeta
plaques devoid of NPY dystrophies. As shown, treated
PS1xAPP mice displayed a small, but significant, in-
crease in the proportion of plaques without associated
NPY dystrophies (Figure 5B). More relevant, when the
NPY dystrophic area was normalized by the correspond-
ing Abeta plaque area, we observed a substantial reduc-
tion of the NPY dystrophic area per plaque in the
treated PS1xAPP mice (Figure 5C). Since this reduction
of the dystrophic area could just reflect the decrease in
plaque size, we also plotted single NPY-dystrophic area
versus the corresponding Abeta plaque area, for both
control and treated PS1xAPP mice. As expected, we ob-
served a significant positive linear correlation between
both parameters in both mice groups (Figure 5D). Im-
portantly, we also observed a significant higher dys-
trophic area in control PS1xAPP mice across all size of
plaques, as compared with treated PS1xAPP mice. In
fact, the slope of the fitted linear regression, between
dystrophic area versus plaque area, presented a 3-fold
decrease after lithium treatment (0.0399 ± 0.006 vs
0.0119 ± 0.0011; for control and lithium PS1xAPP mice;
ANOVA F(1,127) = 27.88, p = 0.00001).
Taken together, these data demonstrated that lithium
treatment modified Abeta plaques quality decreasing
their toxicity measured as the capacity to induce axonal
dystrophies formation.
Lithium treatment induced astrocyte activation and the
incorporation of Hsps to Abeta plaques
Finally, we investigated the possible implication of astrocytes
on this lithium-mediated modification of Abeta plaques.
Activated astrocytes, surrounding Abeta, could highly
influence the Abeta compation and plaque aggregation
[35-37]. Thus, we evaluated whether lithium affected the
astrocyte activation by determining the expression of
GFAP by qPCR (Figure 6A) and immunohistochemistry
(Figure 6B, b1 to b4). As expected, GFAP expression and
astrocyte activation were increased in control PS1xAPP
group (as compared with PS1 mice, Figure 6A and B). As
also shown, lithium treatment produced a higher increased
in GFAP expression (Figure 6A) and also in GFAP activa-
tion (compare Figures 6B, b2 and b4). In fact, in the treated
PS1xAPP mice, astrocytes were more immunoreactive and
clearly hypertrophic, as compared with control PS1xAPP.
However, no significant lithium-dependent differences were
detected on the expression of other factors, such as NGF,
GDNF, NT-5, MMP9, MMP3 or ApoE, (Figure 6C). It is
also noteworthy that lithium treatment has no effect
on GFAP expression on non-Abeta activated astrocytes
(PS1 lithium mice).
Within the different factors and/or processes that could
influence Abeta compaction, it has been demonstrated that
Figure 4 Lithium treatment reduced the size and increased the compaction of the extracellular Abeta plaques. A) Lithium treatment
reduced the size of Abeta deposits. Plaques were immunostained with anti-Abeta42 antibody. Representative images (a1 and a2) and quantitative
analysis (a3 and a4) of Abeta plaque size from the CA1 subfield of control and lithium-treated PS1xAPP mice. (a3) The individual plaque size
(μm2) was quantitatively assessed from 25 sections of 6 different control or lithium treated PS1xAPP mice. (a4) The plaque size distribution was
determined by calculating the number of plaques falling into distinct area categories (ranging from <200 μm2 to >2000 μm2). For each category,
the difference between control and lithium was determined by t-test. so, stratum oriens; sp, stratum pyramidale; sr, stratum radiatum. B) Lithium
treatment increased the Abeta plaque compaction. Signal density of Abeta42 immunostained plaques from control (b1, b2) and lithium-treated
(b3, b4) mice were measured in the CA1 subfield of hippocampus. Optical densities (pixel/μm2) of plaques from 5 sections/mouse and 5 mice
per group was represented in the graph. C) Plaque oligomeric halo, considered as the difference between OC- and Thio-S-stained areas was
reduced by lithium. Plaques were sequentially staining with Thio-S and the OC antibody. (c1-c6) Representative images of a similar size plaque in
the CA1 region of control (c1-c3) or lithium-treated (c4-c6) mice showing the plaque halo. (c7) Similar size plaques (< 200 μm2) were analyzed
(15 plaques per animal, n = 3 mice per group). Scale bars: a1, a2 200 μm; b1-b4 25 μm; c1-c6 20 μm.
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(Hsps), have the capacity to reduce the Abeta toxicity by in-
creasing the sequestration/compaction of putative toxic
Abeta oligomers [36,38-41],. Furthermore, it has been also
demonstrated that astrocytes could express and release dif-
ferent Hsps [36]. Thus, we evaluated whether lithium treat-
ment did affect the Hsps expression. First, we determined,
by western blots, the levels of Hsp27, Hsp60 and Hsp70 in
PS1xAPP control and lithium treated mice. As shown in
Figure 6D, we observed a consistent increase on the levels
of all four proteins in the lithium group. However, no
changes on expression (by qPCR) were detected (not
shown). Moreover, we analyzed the in vivo localization ofHsp70 (not shown) and Hsp27 (Figure 6E) and whether
lithium treatment modified their distribution. Both chap-
erones displayed similar immunostaining patterns. In
lithium treated PS1xAPP mice (Figure 6E e1 to e5),
triple labeling experiments demonstrated that anti-
Hsp27 intense stained the Abeta plaque core (labeled
by 6E10) and, interestingly, also activated astrocytes
(GFAP-positive cells) near plaques displayed Hsp-27
immunopositive puncta. However, in control PS1xAPP
mice, the core of Abeta plaques appeared weakly im-
munostained and low or no immunoreactivity was ob-
served in astrocytes surrounding Abeta plaques
(Figure 6E, e6-e9).
Figure 5 Lithium treatment decreased the Abeta toxicity. A) NPY-labeled dystrophic neurites, surrounding 6E10-labeled Abeta plaques,
were compared in CA1 field of hippocampus from control (a1) and lithium-treated (a2) PS1xAPP mice (5 sections per mice, 3 mice per group).
B) Lithium treatment increased the proportion of Abeta plaques displaying no apparent NPY-dystrophies. The difference between groups
(indicated in the figure) was assessed using t-test. C) Lithium also significantly (using non-parametric Wilcoxon test) reduced the NPY dystrophic area,
normalized by the corresponding plaque area. D) The decrease on Abeta toxicity, at all plaque sizes, was also assessed by plotting the individual NPY
dystrophic area versus Abeta plaque area. The individual data from both groups were fitted to a linear model and the possible difference between
groups was analyzed using Multiple Regression Analysis. As shown, both groups (control and lithium) could be fitted to a linear model and both
regression lines were statistically different (ANOVA F(3,145) = 38.00; p = 0.00001). Furthermore, the slopes of the fitted data were also significantly
different between both groups (Conditional Sum of Squares, see Results). Scale bars: a1 25 μm, a2 50 μm.
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data indicated that lithium, modulating the production/
release of Hsps by astrocytes, might decrease the toxicity
of plaques by increasing the Abeta compaction.
Discussion
Here, we demonstrate that chronic oral administration
of lithium, before the pathology onset, resulted in less
toxic plaque formation that significantly ameliorated the
degenerative processes and behavioral/memory deficits
occurring during disease progression in our PS1xAPP
model. Specifically, and of great relevance for AD pre-
vention, early lithium intervention was able to arrest
neuronal loss in hippocampus and entorhinal cortex of
highly vulnerable populations, Beside, lithium substan-
tially reduced the axonal dystrophic pathology, associ-
ated to amyloid plaques, by increasing the Abeta
compaction. As we discuss below, these neuroprotectiveeffects of lithium could be mediated by modifications of
the plaque toxicity through the astrocytic release of heat
shock proteins. On contrary to previous failed clinical
studies using lithium, our results highlight the potential
use of this compound as a preventive intervention to
halt/slow AD pathology progression at preclinical stages.
As we reported previously, our PS1xAPP mouse
displays early (6 months) neuronal loss affecting SOM/NPY
GABAergic cells in the hippocampal formation and
entorhinal cortex, which coincides spatiotemporally
with the extracellular Abeta deposition [15,16,23,24,30,31].
In addition, another pathological feature of this AD
model is the formation of abundant axonal dystro-
phies surrounding the Abeta plaques. Dystrophies accu-
mulated phosphorylated tau, ubiquitinated proteins and
autophagic vesicles [15,16].
Our data demonstrate that lithium administration, start-
ing before the beginning of the neurodegenerative
Figure 6 Lithium increased the astrocyte activation and the Hsps levels. A-B) Lithium treatment increased the astrocyte activation assessed
by qPCR (A) and GFAP immunoreactivity (B). GFAP expression (A) was assayed in hippocampal samples from 10 mice per group. GFAP expression
increased in PS1xAPP control group and further increased in PS1xAPP lithium-treated mice. ANOVA (F(3,36) = 18.82, p = 0.0001). The post-hoc analysis
using Tukey is presented in the graph. B) Representative confocal images through the CA1 field of control (b1, b2) and lithium-treated (b3, b4) mice,
showing GFAP-immunoreactive astrocytes (red) and Thioflavin-stained Abeta plaques (green). As shown, GFAP immunoreactivity is clearly higher in
lithium-treated mice. C) Lithium did not modify the expression of NGF,GDNF, NT-5, MMP9, MMP3 or ApoE, determined by qPCR (n = 4 mice per
group). D) Lithium treatment increased the levels of three Hsps (Hsp70, Hsp60 and Hsp27). Representative western blots and quantitative analysis of
Hsps using protein extract from hippocampus of control and lithium-treated PS1xAPP mice (n = 4 mice per group). The expression of all three Hsps
was normalized using PS1 control (not shown), and the significance was determined by t-test. E) Confocal images through the CA1 subfield showing
GFAP/Hsp27/Abeta triple immunofluorescence labeling. In lithium-treated mice (e1-e5), the core of the Abeta plaques (labeled by 6E10, in blue) is
intensely stained with the anti-Hsp27 antibody (in red), as well as astrocytic puncta processes (labeled by GFAP, in green) surrounding the plaques
(see insert in e2 showing double GFAP-Hsp27 labeling, and the triple labeling detail in e5). On the contrary, in control mice (e6-e9), the core of the
Abeta plaques appears almost devoid of Hsp27 immunostaining and low or no immunoreactivity was observed in astrocytes surrounding the plaques.
Scale bars, d1-d9 20 μm, insert in a2 10 μm.
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NPY cells in both the hippocampus and entorhinal cortex.
This is the first report showing that lithium prevents neur-
onal loss in AD vulnerable brain regions using in vivo stud-
ies. Also, our data demonstrate that lithium ameliorates
the dystrophic pathology, reducing dramatically the
NPY-positive dystrophic area associated to the Abeta
plaques and decreasing the levels of abnormally accu-
mulated LC3-II, AT8 and ubiquitinated proteins. Thus, lith-
ium clearly alleviates most of the neuropathological signs of
the PS1xAPP model.As we and others have demonstrated, the PS1xAPP mice
display GSK-3beta activation and autophagy/lysosomal
deficiencies [15,16,31,42,43]. Lithium could directly affect
the neuronal degeneration by inhibiting the GSK-3beta
activity (data not shown; [44]) and/or by activating the
autophagy-mediated protein degradation [12,45,46]. These
effects would reduce the accumulation of phospho-tau,
LC3-II and ubiquitinated proteins and, in consequence, re-
duce the neurodegenerative process. However, the PS1xAPP
transgenic model accumulates these proteins in axonal
dystrophies surrounding the Abeta plaques. In this sense, we
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dystrophies might be directly implicated in the neuronal
degeneration during disease progression [9,15,16,47,48]. This
suggestion agrees with recent data from AD patients [49].
Importantly, quantitative data demonstrate that lithium pro-
duced a prominent reduction (−60%) of the NPY-positive
dystrophic area. This reduction could also be reflected by the
decrease in the abnormal accumulation of phospho-tau,
LC3-II and ubiquitinated proteins, associated with the
dystrophic pathology, surrounding Abeta plaques.
Therefore, besides a putative direct effect either
through GSK-3beta activity or autophagy/lysosomal pro-
tein degradation, the lithium-mediated amelioration of
the neuropathological alterations may likely reflect the
dramatic reduction in the formation of dystrophic neur-
ites around the Abeta plaques. This effect could also re-
flect the lithium-dependent modifications of the Abeta
plaque formation.
As we have shown here, lithium produced a prominent
change in plaque morphology and quality. In fact, the
Abeta plaques were smaller (see also [20]) and more
compact in treated than in control PS1xAPP mice. In
this context, it has been reported that the highly aggre-
gated Abeta possesses a reduced toxicity [33,50], and
therefore the observed decrease in the dystrophic area
per plaque could reflect a reduction in plaque toxicity.
Regarding the plaque toxicity, it has been noted that
the formation of axonal dystrophies and the synaptic
degeneration seemed to be restricted to the periphery of
the Abeta plaques [34,48,50]. This most periphery area
(halo) of the plaques might be constituted by partially
aggregated Abeta fibrillar oligomers, which could be
involved on the AD pathology [51]. In this scenario, our
data demonstrate that lithium produces a reduction on
the fibrillar oligomeric halo (which is recognized by the
conformation specific polyclonal OC antibody) of the Abeta
plaques, thus diminishing the plaque toxicity.
The processes contributing in the Abeta aggregation,
plaque formation or plaque compaction are actually
unknown. It has been suggested that astrocytes could play
a prominent role by limiting the plaque growth and the
plaque-associated dystrophy formation [35,36]. Moreover,
activated astrocytes may release, among different factors,
Hsps [52,53], which could induce the Abeta aggregation, re-
ducing its potential toxicity [36,38,40]. In agreement with
these data, our results strongly suggest the involvement of
astrocytes and extracellular Hsps as mediators of the lithium
effect on plaque toxicity. In fact, we demonstrate simultan-
eous higher astrocyte activation with higher incorporation
of Hsps in the Abeta plaques and reduced oligomeric plaque
halo in lithium treated PS1xAPP mice, compared with
controls. It is noteworthy the lithium-dependent increase of
Hsp70 and Hsp27 in the plaque core. Although further
experiments should be done, this particular localizationsuggests that these Hsps could be implicated in the Abeta
nucleation and plaque compaction.
Conclusions
Our data demonstrate that the early chronic lithium
treatment significantly ameliorates the pathological
progression in this PS1xAPP AD model. Lithium could
reduce neuronal/axonal degeneration by increasing the
Abeta compaction and, in consequence, producing smaller
Abeta plaques with lower toxic halo. Lithium could
influence directly neurons but, as we have shown in
this work, this compound has a novel therapeutic effect
through astrocytes inducing chaperones release which have
the capacity to modulate the Abeta compaction/toxicity.
To the best of our knowledge, this is the first time that this
therapeutic effect of lithium on Abeta plaque quality has
been reported. These data reveal a novel lithium-mediated
mechanism capable of altering the course of the disease
in an amyloidogenic AD model. These Abeta-modifying
mechanism might represent an innovative therapeutic
approach to the, so far, continuing negative outcomes of
AD clinical trials aimed to clear Abeta plaques once they
have already formed, and to the current inability to
prevent plaques from forming in the first place.
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